Scarica l'app Stockscreener
167.76
0.71%
1.19
Pre-mercato:
168.09
0.33
+0.20%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ABBV Giù?
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$166.57
Aprire:
$166.91
Volume 24 ore:
4.27M
Relative Volume:
0.86
Capitalizzazione di mercato:
$294.70B
Reddito:
$55.53B
Utile/perdita netta:
$5.12B
Rapporto P/E:
45.96
EPS:
3.65
Flusso di cassa netto:
$15.62B
1 W Prestazione:
-1.52%
1M Prestazione:
-11.17%
6M Prestazione:
+1.94%
1 anno Prestazione:
+21.29%
Intervallo 1D:
$165.65
$167.91
Intervallo di 1 settimana:
$163.81
$171.62
Portata 52W:
$137.65
$207.32
Abbvie Inc Stock (ABBV) Company Profile
Nome
Abbvie Inc
Settore
Industria
Telefono
(847) 932-7900
Indirizzo
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Confronta ABBV con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| ABBV | 167.76 | 294.70B | 55.53B | 5.12B | 15.62B | 3.65 |
| LLY | 753.41 | 693.54B | 40.86B | 8.37B | -2.28B | 5.4193 |
| NVO | 105.27 | 465.74B | 39.36B | 13.79B | 9.83B | 2.4077 |
| JNJ | 153.11 | 353.35B | 87.70B | 14.68B | 19.03B | 13.47 |
| MRK | 97.44 | 248.54B | 63.17B | 12.15B | 14.84B | 1.80 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-06-05 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-05-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-01-29 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | Downgrade | HSBC Securities | Buy → Hold |
| 2023-12-11 | Aggiornamento | Goldman | Neutral → Buy |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-10-30 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-09-29 | Iniziato | Raymond James | Outperform |
| 2023-07-25 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-04-05 | Downgrade | Argus | Buy → Hold |
| 2023-03-01 | Iniziato | Guggenheim | Buy |
| 2023-02-22 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | Aggiornamento | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-11-08 | Downgrade | Societe Generale | Buy → Hold |
| 2022-08-01 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | Iniziato | SVB Leerink | Underperform |
| 2022-05-06 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2022-02-28 | Downgrade | UBS | Buy → Neutral |
| 2022-02-03 | Reiterato | BMO Capital Markets | Outperform |
| 2022-02-03 | Reiterato | Barclays | Equal Weight |
| 2022-02-03 | Reiterato | BofA Securities | Neutral |
| 2022-02-03 | Reiterato | Goldman | Neutral |
| 2022-01-13 | Iniziato | Redburn | Buy |
| 2022-01-12 | Reiterato | BMO Capital Markets | Outperform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-11-23 | Aggiornamento | Societe Generale | Hold → Buy |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2020-11-10 | Ripresa | Bernstein | Outperform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-06-23 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | Aggiornamento | Argus | Hold → Buy |
| 2020-05-18 | Ripresa | BofA/Merrill | Neutral |
| 2020-05-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-05-11 | Ripresa | Morgan Stanley | Overweight |
| 2020-04-20 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | Downgrade | Societe Generale | Buy → Hold |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | Reiterato | Cowen | Outperform |
| 2019-09-26 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-08-20 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | Iniziato | Goldman | Neutral |
| 2019-04-29 | Aggiornamento | BMO Capital Markets | Underperform → Market Perform |
Mostra tutto
Abbvie Inc Borsa (ABBV) Ultime notizie
AbbVie Insiders Sold US$56m Of Shares Suggesting Hesitancy - Yahoo Finance
AbbVie (NYSE:ABBV) Stock Price Up 0.1% Following Analyst Upgrade - MarketBeat
Altman Advisors Inc. Boosts Holdings in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Advisors Asset Management Inc. Sells 39,044 Shares of AbbVie Inc. (NYSE:ABBV) - MarketBeat
Is Trending Stock AbbVie Inc. (ABBV) a Buy Now? - Yahoo Finance
Ontario Teachers Pension Plan Board Has $580.18 Million Stake in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Jennison Associates LLC Purchases 145,542 Shares of AbbVie Inc. (NYSE:ABBV) - MarketBeat
Howe & Rusling Inc. Grows Stock Holdings in AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie Inc. (NYSE:ABBV) Shares Sold by Commerce Bank - MarketBeat
AbbVie Inc. stock rises Tuesday, still underperforms market - MarketWatch
AbbVie (NYSE:ABBV) Trading Down 0.7%Here's What Happened - MarketBeat
Counterweight Ventures LLC Raises Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie Inc. (NYSE:ABBV) Shares Purchased by Avior Wealth Management LLC - MarketBeat
AbbVie (NYSE:ABBV) Price Target Raised to $195.00 at Wells Fargo & Company - MarketBeat
Where Will AbbVie Be in 5 Years? - Yahoo Finance
PNC Financial Services Group Inc. Lowers Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
B. Metzler seel. Sohn & Co. Holding AG Makes New $89.42 Million Investment in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Banque Cantonale Vaudoise Purchases 4,650 Shares of AbbVie Inc. (NYSE:ABBV) - MarketBeat
Beddow Capital Management Inc. Has $7.09 Million Stock Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie Inc. (NYSE:ABBV) Shares Bought by Fifth Third Wealth Advisors LLC - MarketBeat
AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.64 - Simply Wall St
AbbVie Inc. (NYSE:ABBV) Shares Bought by Meeder Asset Management Inc. - MarketBeat
Caprock Group LLC Grows Stake in AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie Inc. (NYSE:ABBV) Shares Acquired by Quest Partners LLC - MarketBeat
EC grants approval for AbbVie’s Elahere in ovarian cancer - The Pharma Letter
Thrivent Financial for Lutherans Boosts Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
What is a ‘cure,’ really? AbbVie’s Humira creator leaps into the next phase of medicine - Yahoo Finance
Regenerative Medicine Industry May See a Big Move | AbbVie, ViaCyte, Cook Biotech - openPR
AbbVie Inc. (NYSE:ABBV) Short Interest Up 12.1% in October - MarketBeat
AbbVie snaps eight straight sessions of losses - MSN
AbbVie (NYSE:ABBV) Trading Up 0.2%Time to Buy? - MarketBeat
Mawer Investment Management Ltd. Sells 14,746 Shares of AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie's Ovarian Cancer Drug Elahere Gets Approval in Europe - Yahoo Finance
Napa Wealth Management Buys Shares of 11,771 AbbVie Inc. (NYSE:ABBV) - MarketBeat
Allergan Aesthetics Offers Free Business Education Courses Online to Support Growing Practices with Allergan Aesthetics Products - AbbVie
Allergan Aesthetics Launches Free Business Training Platform for Healthcare Practices | ABBV Stock News - StockTitan
GLOBALT Investments LLC GA Invests $3.78 Million in AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie Inc. (NYSE:ABBV) Shares Bought by Richard C. Young & CO. LTD. - MarketBeat
Aldeyra's Dry Eye Drug Gets FDA Review, Expands $400M AbbVie Partnership Deal | ALDX Stock News - StockTitan
Aljian Capital Management LLC Invests $1.33 Million in AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie Inc. (NYSE:ABBV) Shares Sold by MAI Capital Management - MarketBeat
AbbVie Inc. (NYSE:ABBV) Shares Sold by AMG National Trust Bank - MarketBeat
AbbVie bags EU nod for key drug from ImmunoGen takeover - pharmaphorum
AbbVie Gets European OK of Elahere in Platinum-Resistant Ovarian Cancer - MarketWatch
AbbVie’s Elahere wins European approval for certain ovarian cancers - Pharmaceutical Technology
AbbVie Receives European Commission Approval of ELAHERE® (mirvetuximab soravtansine) for the Treatment of Platinum-Resistant Ovarian Cancer - PR Newswire
AbbVie's (NYSE:ABBV) Shareholders Will Receive A Bigger Dividend Than Last Year - Yahoo Finance
Atlanta Consulting Group Advisors LLC Acquires Shares of 5,060 AbbVie Inc. (NYSE:ABBV) - MarketBeat
Sawgrass Asset Management LLC Has $13.61 Million Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie Inc. (NYSE:ABBV) Shares Sold by Mutual of America Capital Management LLC - MarketBeat
Why AbbVie’s (ABBV) Drug Setback Creates A Prime Buy-The-Dip Moment - MSN
Abbvie Inc Azioni (ABBV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.93%
0.17%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):